Project Grant HT94252410566
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$539K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This $168,042 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, for in vivo targeting of TFE3 dimerization partners in translocation renal cell carcinoma (RCC) research. The award period runs from August 1, 2025 to July 31, 2026. The grant supports advanced biomedical research initiatives focused on transforming...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded a $772,626 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, effective from August 1, 2025 to July 31, 2028, will fund preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston,...
This federal Project Grant award for $1,428,720.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Brigham & Women's Hospital Inc. to investigate the protein degradation of menin and KMT2A for the treatment of myeloid neoplasms. The research aims to develop novel therapeutic approaches for myeloid neoplasms, which are a group of blood cancers. The project will be conducted over a 4-year period from August...
The Department of Defense's Defense Health Agency awarded a $820,833 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports a research project to "Identify the Liver Microenvironment that Drives Uveal Melanoma Metastasis and Immunity." The 3-year award, effective from...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $947,746 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "IDENTIFICATION OF THE LIVER MICROENVIRONMENT THAT DRIVES UVEAL MELANOMA METASTASIS AND IMMUNITY". The 3-year grant, beginning on September 1, 2024 and ending on August 31, 2027, will enable DFCI, a non-profit cancer research center in Boston, MA, to investigate the liver...